Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral MOA-728 for Opioid-Induced Bowel Dysfunction in Chronic Non-Malignant Pain
2006-002414-35Phase 2Completed
- Sponsor
- Wyeth
- Start
- Aug 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of methylnaltrexone in opioid-induced bowel dysfunction (OIBD) (4 arms), sponsored by Wyeth. Primary endpoint: Change in spontaneous bowel movements per week. Started Aug 2006; status: completed.
02
Drugs
methylnaltrexone
03
Conditions
opioid-induced bowel dysfunction (OIBD)
Beyond the preview
Go deeper on 2006-002414-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-002414-35.